Jazz Pharmaceuticals: One Step Forward, One Back

Jazz Pharmaceuticals faces increasing competition in its oxybate franchise as Avadel can now commercialize Lumryz for idiopathic hypersomnia, while also advancing its oncology pipeline with potential FDA decisions on dordaviprone and Zepzelca, and Phase 3 results for zanidatamab expected in the second half of the year; these oncology developments are critical to offsetting anticipated oxybate revenue declines. Jazz acquired Chimerix for $935 million to diversify its revenue stream, but faces both regulatory and clinical risks associated with dordaviprone. Despite a strong start to the year, the stock has declined 22% due to macro factors and drug pricing concerns.

Analysis

Jazz Pharmaceuticals (JAZZ) began the year with a reported Q4 2024 revenue beat and issued 2025 revenue guidance marginally below analyst consensus, yet its stock has fallen 22% since February, impacted by macroeconomic factors like tariff-driven selloffs and industry-specific drug pricing concerns, such as President Trump’s Most Favored Nation executive order. The company's oxybate franchise faces significant headwinds; competitor Avadel Pharmaceuticals (AVDL) secured an appeal victory allowing Lumryz development for idiopathic hypersomnia, directly challenging Jazz's Xywav, which currently holds exclusivity in this market. In narcolepsy, while Xywav maintains a larger patient base (10,400 patients versus Lumryz's 2,800 as of Q1), Lumryz has demonstrated stronger recent patient acquisition, adding approximately 2,800 patients compared to Xywav's 900 since its launch. These competitive pressures are expected to escalate with unlimited generic Xyrem availability from 2026. To diversify, Jazz acquired Chimerix for $935 million, gaining dordaviprone for H3 K27M-mutant diffuse glioma; this drug candidate is under FDA Priority Review with a PDUFA date in August and, if approved, could yield a Priority Review Voucher valued around $150 million. Dordaviprone has projected revenues of $382 million by 2030 but is subject to regulatory and clinical approval risks based on an accelerated pathway. Crucially, Jazz's oncology pipeline presents key inflection points in the second half of the year, including regulatory decisions for dordaviprone and Zepzelca (first-line small-cell lung cancer), and the critical Phase 3 readout for zanidatamab in first-line gastroesophageal adenocarcinoma. Positive outcomes in oncology are vital to offset anticipated oxybate revenue deterioration and could potentially drive double-digit topline growth in the latter half of the decade. Despite these challenges, Jazz's U.S.-centric operations offer some insulation from certain international drug pricing risks.

Key Decisions for Investors

• Investors should closely monitor the competitive dynamics affecting Jazz's oxybate franchise, particularly Lumryz's market penetration in narcolepsy and its anticipated entry into idiopathic hypersomnia, as well as the impact of full generic Xyrem availability from 2026.
• The upcoming regulatory decisions for dordaviprone and Zepzelca, alongside the pivotal Phase 3 readout for zanidatamab in the second half of the year, represent key catalysts that could significantly influence Jazz's valuation and growth outlook.
• Evaluate the strategic execution and financial contribution of the $935 million Chimerix acquisition, focusing on dordaviprone's approval prospects, market adoption, and the potential monetization of its Priority Review Voucher against inherent clinical and regulatory risks.
• Considering the stock's 22% decline, assess whether current valuation adequately reflects the pressures on the oxybate business versus the transformative potential of the oncology pipeline, especially given the company's relative positioning against certain drug pricing initiatives.